Effect of Angiotensin-Converting Enzyme Inhibitors on Physical Function in Elderly Subjects: A Systematic Review and Meta-Analysis

Drugs and Aging

Volumn 32, Issue 9, 2015, Pages 727-735

  Zhou, Ling shan ^a   Xu, Ling jie ^a   Wang, Xue qing ^a   Huang, Yi huan ^a   Xiao, Qian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

AGED; DRUG EFFECT; GRIP STRENGTH; HUMAN; META ANALYSIS; PHYSICAL ACTIVITY, CAPACITY AND PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; WALKING;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84942504814     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-015-0288-3     Document Type: Review

References (63)

1. Hida T, Harada A, Imagama S, Ishiguro N. Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations. Aging Dis. 2014;5(4):226–37.
2. Cruz-Jentoft AJ, Landi F, Topinkova E, Michel JP. Understanding sarcopenia as a geriatric syndrome. Curr Opin Clin Nutr Metab Care. 2010;13(1):1–7.
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.
4. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. 2011;12(4):249–56.
5. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. Front Aging Neurosci. 2014;6:192.
6. Cesari M, Rolland Y, Abellan Van Kan G, Bandinelli S, Vellas B, Ferrucci L. Sarcopenia-related parameters and incident disability in older persons: results from the “Invecchiare in Chianti” Study. J Gerontol A Biol Sci Med Sci. 2015;70(4):457–63.
7. Isoyama N, Qureshi AR, Avesani CM, et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. Clin J Am Soc Nephrol. 2014;9(10):1720–8.
8. Lang IA, Llewellyn DJ, Alexander K, Melzer D. Obesity, physical function, and mortality in older adults. J Am Geriatr Soc. 2008;56(8):1474–8.
9. Nishiguchi S, Yamada M, Fukutani N, et al. Differential association of frailty with cognitive decline and sarcopenia in community-dwelling older adults. J Am Med Dir Assoc. 2015;16(2):120–4.
10. Tanimoto Y, Watanabe M, Sun W, et al. Association between sarcopenia and higher-level functional capacity in daily living in community-dwelling elderly subjects in Japan. Arch Gerontol Geriatr. 2012;55(2):e9–13.
11. Yamada M, Nishiguchi S, Fukutani N, et al. Prevalence of sarcopenia in community-dwelling Japanese older adults. J Am Med Dir Assoc. 2013;14(12):911–5.
12. Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80–5.
13. Lee HC, Lee ML, Kim SR. Effect of exercise performance by elderly women on balance ability and muscle function. J Phys Ther Sci. 2015;27(4):989–92.
14. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev. 2009;3:CD002759.
15. Rhee CM, Kalantar-Zadeh K. Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients? J Cachexia Sarcopenia Muscle. 2014;5(3):177–80.
16. Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens. 2008;26(5):1037–42.
17. Ochi M, Kohara K, Tabara Y, et al. Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men. Atherosclerosis. 2010;212(1):327–32.
18. Sayer G, Bhat G. The renin–angiotensin–aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21–32, vii.
19. Mavros Y, Kay S, Simpson KA, et al. Reductions in C-reactive protein in older adults with type 2 diabetes are related to improvements in body composition following a randomized controlled trial of resistance training. J Cachexia Sarcopenia Muscle. 2014;5(2):111–20.
20. Zembron-Lacny A, Dziubek W, Rogowski L, Skorupka E, Dabrowska G. Sarcopenia: monitoring, molecular mechanisms, and physical intervention. Physiol Res. 2014;63(6):683–91.
21. Churchward-Venne TA, Breen L, Phillips SM. Alterations in human muscle protein metabolism with aging: protein and exercise as countermeasures to offset sarcopenia. Biofactors. 2014;40(2):199–205.
22. Calvani R, Joseph AM, Adhihetty PJ, et al. Mitochondrial pathways in sarcopenia of aging and disuse muscle atrophy. Biol Chem. 2013;394(3):393–414.
23. Alway SE, Myers MJ, Mohamed JS. Regulation of satellite cell function in sarcopenia. Front Aging Neurosci. 2014;6:246.
24. Woo J, Yu R, Tang N, Leung J. Telomere length is associated with decline in grip strength in older persons aged 65 years and over. Age. 2014;36(5):9711.
25. Premaratna SD, Manickam E, Begg DP, et al. Angiotensin-converting enzyme inhibition reverses diet-induced obesity, insulin resistance and inflammation in C57BL/6J mice. Int J Obes (Lond). 2012;36(2):233–43.
26. de Cavanagh EM, Piotrkowski B, Basso N, et al. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003;17(9):1096–8.
27. de Cavanagh EM, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol. 2000;278(3):R572–7.
28. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes. 2006;55(2):367–74.
29. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ. 2007;177(8):867–74.
30. Sumukadas D, Band M, Miller S, et al. Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2014;69(6):736–43.
31. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011. http://handbook.cochrane.org/. Accessed 22 Jun 2014.
32. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660–4.
33. Buford TW, Manini TM, Hsu FC, et al. Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise. J Am Geriatr Soc. 2012;60(7):1244–52.
34. Cao YJ, Mager DE, Simonsick EM, et al. Physical and cognitive performance and burden of anticholinergics, sedatives, and ACE inhibitors in older women. Clin Pharmacol Ther. 2008;83(3):422–9.
35. Cesari M, Kritchevsky SB, Baumgartner RN, et al. Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study. Am J Clin Nutr. 2005;82(2):428–34.
36. Di Bari M, van de Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc. 2004;52(6):961–6.
37. Gray SL, Aragaki AK, LaMonte MJ, et al. Statins, angiotensin-converting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc. 2012;60(12):2206–14.
38. Gray SL, LaCroix AZ, Aragaki AK, et al. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: prospective findings from the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2009;57(2):297–303.
39. Han K, Park YM, Kwon HS, et al. Sarcopenia as a determinant of blood pressure in older Koreans: findings from the Korea National Health and Nutrition Examination Surveys (KNHANES) 2008–2010. PLoS One. 2014;9(1):e86902.
40. Maggio M, Ceda GP, Lauretani F, et al. Relation of angiotensin-converting enzyme inhibitor treatment to insulin-like growth factor-1 serum levels in subjects >65 years of age (the InCHIANTI study). Am J Cardiol. 2006;97(10):1525–9.
41. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359(9310):926–30.
42. Witham MD, Syddall HE, Dennison E, Cooper C, McMurdo ME, Sayer AA. ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study. Age Ageing. 2014;43(5):661–6.
43. Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, McMurdo ME. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart. 2002;88(4):373–7.
44. Bunout D, Barrera G, de la Maza MP, Leiva L, Backhouse C, Hirsch S. Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial. J Renin Angiotensin Aldosterone Syst. 2009;10(2):77–84.
45. Cesari M, Pedone C, Incalzi RA, Pahor M. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc. 2010;11(1):26–32.
46. Bunout D, de la Maza MP, Barrera G, Leiva L, Gattas V, Hirsch S. Assessment of sarcopenia: longitudinal versus cross sectional body composition data. Aging Clin Exp Res. 2007;19(4):295–9.
47. Stone E, Skubic M, Rantz M, Abbott C, Miller S. Average in-home gait speed: investigation of a new metric for mobility and fall risk assessment of elders. Gait Posture. 2015;41(1):57–62.
48. Kutner NG, Zhang R, Huang Y, Wasse H. Gait speed and hospitalization among ambulatory hemodialysis patients: USRDS special study data. World J Nephrol. 2014;3(3):101–6.
49. Donoghue OA, Jansen S, Dooley C, De Rooij S, Van Der Velde N, Kenny RA. Atrial fibrillation is associated with impaired mobility in community-dwelling older adults. J Am Med Dir Assoc. 2014;15(12):929–33.
50. Abellan van Kan G, Rolland Y, Andrieu S, et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009;13(10):881–9.
51. Chan OY, van Houwelingen AH, Gussekloo J, Blom JW, den Elzen WP. Comparison of quadriceps strength and handgrip strength in their association with health outcomes in older adults in primary care. Age. 2014;36(5):9714.
52. Legrand D, Vaes B, Mathei C, Adriaensen W, Van Pottelbergh G, Degryse JM. Muscle strength and physical performance as predictors of mortality, hospitalization, and disability in the oldest old. J Am Geriatr Soc. 2014;62(6):1030–8.
53. Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. BMJ. 2010;341:c4467.
54. Onder G, Della Vedova C, Landi F. Validated treatments and therapeutics prospectives regarding pharmacological products for sarcopenia. J Nutr Health Aging. 2009;13(8):746–56.
55. Murphy KT, Chee A, Trieu J, Naim T, Lynch GS. Inhibition of the renin–angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia. Int J Cancer. 2013;133(5):1234–46.
56. Morales MG, Cabrera D, Cespedes C, et al. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2). Cell Tissue Res. 2013;353(1):173–87.
57. Marzetti E, Calvani R, DuPree J, et al. Late-life enalapril administration induces nitric oxide-dependent and independent metabolic adaptations in the rat skeletal muscle. Age. 2013;35(4):1061–75.
58. Carter CS, Giovannini S, Seo DO, et al. Differential effects of enalapril and losartan on body composition and indices of muscle quality in aged male Fischer 344x Brown Norway rats. Age. 2011;33(2):167–83.
59. Minami N, Li Y, Guo Q, et al. Effects of angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle. J Hypertens. 2007;25(6):1241–8.
60. Kanazawa M, Kawamura T, Li L, et al. Combination of exercise and enalapril enhances renoprotective and peripheral effects in rats with renal ablation. Am J Hypertens. 2006;19(1):80–6.
61. Guo Q, Minami N, Mori N, et al. Effects of estradiol, angiotensin-converting enzyme inhibitor and exercise training on exercise capacity and skeletal muscle in old female rats. Clin Exp Hypertens. 2010;32(2):76–83.
62. Williams AG, Rayson MP, Jubb M, et al. The ACE gene and muscle performance. Nature. 2000;403(6770):614.
63. Montgomery H, Clarkson P, Barnard M, et al. Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training. Lancet. 1999;353(9152):541–5.